Drug Profile


Alternative Names: Depsipeptide; FK 228; FR 901228; Istodax; NSC 630176; NSC 630176D

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Developer Celgene Corporation; Lymphoma Academic Research Organisation; University of Birmingham; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytostatic antibiotics; Depsipeptides; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Phase I/II Multiple myeloma; T cell lymphoma; T-cell leukaemia
  • Phase I Haematological malignancies
  • Discontinued Pancreatic cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 24 Mar 2017 Sidney Kimmel Cancer Center at Thomas Jefferson University terminates phase I/II trial in Breast cancer (Newly diagnosed, Combination therapy, Metastatic disease) in USA (IV) (NCT01938833)
  • 24 Feb 2017 Phase I/II development is ongoing in Multiple myeloma (Combination therapy, Second-line or greater) in USA (IV) (NCT01755975)
  • 03 Dec 2016 Efficacy, safety and pharmacokinetics data from a phase I/II trial in Peripheral T-cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top